Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetic dyslipidemia.

Tina J Chahil1, Henry N Ginsberg

  • 1Department of Medicine, College of Physicians and Surgeons of Columbia University, PH 10-305, 630 West 168th Street, New York, NY 10032, USA.

Endocrinology and Metabolism Clinics of North America
|September 9, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triglyceride-Rich Lipoprotein Metabolism and Cardiovascular Risk in Diabetes: Bedside to Bench to Bedside.

Circulation research·2026
Same author

Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: What we know and what we need to know.

Atherosclerosis·2025
Same author

ApoB: The intracellular protein detection dilemma in lipoprotein biology.

Biochimica et biophysica acta. Molecular and cell biology of lipids·2025
Same author

In Memoriam: Scott M. Grundy (1933-2025).

Journal of lipid research·2025
Same author

Corrigendum to "Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA" [Atherosclerosis (2025) 403 119114].

Atherosclerosis·2025
Same author

Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA.

Atherosclerosis·2025

Type 2 diabetes mellitus significantly raises cardiovascular disease risk due to complex dyslipidemia. Aggressive treatment of diabetic dyslipidemia, involving managing very-low-density lipoprotein (VLDL), high-density lipoprotein (HDL), and low-density lipoprotein (LDL), is crucial.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Disorders

Background:

  • Type 2 diabetes mellitus (T2DM) is strongly linked to increased cardiovascular disease (CVD) risk.
  • Insulin resistance in T2DM patients underlies a complex dyslipidemia.
  • This dyslipidemia is a primary driver of elevated CVD risk.

Purpose of the Study:

  • To highlight the critical role of dyslipidemia in T2DM-associated cardiovascular risk.
  • To emphasize the central mechanism of increased very-low-density lipoprotein (VLDL) secretion.
  • To advocate for aggressive management of diabetic dyslipidemia.

Main Methods:

  • Review of existing literature on T2DM pathophysiology and dyslipidemia.
  • Analysis of the relationship between insulin resistance, VLDL, HDL, and LDL.

Related Experiment Videos

  • Discussion of available therapeutic strategies.

    • Main Results:

    • Increased hepatic VLDL secretion is a key feature of T2DM dyslipidemia.
    • This contributes to abnormal levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL).
    • The complex lipid profile significantly elevates CVD risk.

    Conclusions:

    • Diabetic dyslipidemia is a major contributor to cardiovascular complications in T2DM.
    • Comprehensive management strategies are necessary to mitigate this risk.
    • Physiologic and pharmacologic interventions should be aggressively employed.